Latest From MorphoSys AG
Although there was no major acquisition starting out the J.P. Morgan Healthcare Conference, the deal-making flow has been steady. Pfizer licensed a neurodegenerative disease candidate to Biogen, while also selling Axsome rights to reboxetine in narcolepsy and fibromyalgia. Biogen signed a neurology R&D collaboration with CAMP4 as well.
MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.
Highlights of year-end application submissions including candidates from AstraZeneca, BioMarin, Lilly, MorphoSys, and Seattle Genetics.
2019 has seen European biotech companies making waves in the US IPO space. Genmab’s listing was a blockbuster, but many more companies have proven their ability to go public on the NASDAQ.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- MorphoSys AG
- Senior Management
Simon E Moroney, PhD, CEO
Jens Holstein, CFO
Malte Peters, MD, Chief Dev. Officer
Markus Enzelberger , PhD, CSO
- Contact Info
Phone: (49) 89 899 27 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.